Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...
A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...
inews.co.uk on MSN
We were told we had cancer on same day. My mum died but I survived
A mum and her daughter were both told they had cancer on the same day – within just hours of […] ...
According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%.
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
DelveInsight's BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
Maternity care bundle for UK women with multiple long-term health conditions: coproduction workshops
Objective The objective of this study is to co-produce a care bundle for women with multiple long-term health conditions (MLTC) that could be pilot tested and implemented in UK maternity services.
Biologic heterogeneity in myeloma supports subtype-specific approaches, and t(4;14) defines a clinically meaningful subset with distinct pathway activation and historically aggressive behavior.
His passing came after a five-year battle with multiple myeloma, a cancer that begins in the plasma cells in the bone marrow, according to a friend of his.
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results